Mitotane for Dogs: Dosage by Weight, Cushing’s Induction, Monitoring & Safety

Mitotane is an adrenocorticolytic medicine used in dogs with Cushing’s disease to reduce excessive adrenal cortisol production by selectively damaging cortisol-producing regions of the adrenal cortex. It is an older treatment than trilostane and is no longer the first medical choice for most dogs, but it remains clinically relevant in selected cases, including some dogs with calcinosis cutis, atypical hyperadrenocorticism or situations in which trilostane is unsuitable or ineffective.

Dog Medication Math Calculator

Enter your dog’s current body weight, then use only the dose already provided by your veterinarian or pharmacy label. The calculator converts lb/kg and can work out mg and liquid mL. It does not choose or recommend a dose.

Dose information from your veterinarian

Optional liquid conversion

Use the exact concentration printed on the current bottle. Different refills can have different strengths.
Safety check: This tool performs arithmetic only. It does not decide whether a drug is appropriate, choose a dose, frequency or duration, or replace a veterinarian. If the entered dose or concentration does not exactly match the prescription, stop and verify it before giving medication. See Dog Weight Converter and Dog Liquid Medication mg-to-mL Calculator.

Mitotane is not a routine “cortisol blocker.” Its induction phase intentionally suppresses adrenal tissue, which means the margin between useful control and excessive adrenal destruction deserves close monitoring. Owners need clear written instructions about appetite, water intake, vomiting, diarrhea, weakness and when to stop the medicine and call the clinic.

What Cushing’s disease is

Canine hyperadrenocorticism is a state of chronic cortisol excess. In most dogs, the cause is a pituitary tumor that produces too much ACTH, stimulating both adrenal glands. A smaller group has a cortisol-producing adrenal tumor. Long-term corticosteroid treatment can also create Cushing-like signs, but that iatrogenic form is managed differently.

Common signs include excessive thirst and urination, increased appetite, panting, muscle weakness, a pot-bellied appearance, thinning skin, recurrent infection and hair loss. Those signs overlap with many other diseases, so endocrine testing should establish the diagnosis before adrenocortical suppression begins.

How mitotane works

Mitotane is related to the insecticide DDD but is used medicinally because it has selective toxic effects on parts of the adrenal cortex. It damages the zona fasciculata and zona reticularis, where glucocorticoids and some adrenal sex hormones are produced. With sufficient exposure it can also affect the zona glomerulosa, which produces mineralocorticoids.

That last point explains the major safety concern. Too much adrenal destruction can create hypoadrenocorticism, including deficiencies of both cortisol and aldosterone.

Mitotane dosage by weight: induction and maintenance are different phases

Merck currently describes mitotane induction for pituitary-dependent Cushing disease at 25–50 mg/kg by mouth every 24 hours, or 12.5–25 mg/kg every 12 hours, usually for 7–10 days before response testing. This induction phase is intentionally different from later maintenance therapy.

Treatment phasePublished canine guidanceWhy it matters
Induction25–50 mg/kg PO every 24 hours, or 12.5–25 mg/kg every 12 hoursUsually followed for 7–10 days with clinical monitoring
ReassessmentACTH stimulation testing after induction or earlier if appetite/water intake fallsPrevents excessive adrenal suppression
MaintenanceIndividualized after induction responseDo not continue induction dosing indefinitely

Source: Merck Veterinary Manual Cushing disease guidance. Mitotane is one of the clearest examples of why a generic “dose-by-weight calculator” would be unsafe without phase and monitoring context.

Why treatment usually has an induction phase

Mitotane therapy has traditionally begun with a loading or induction period designed to reduce adrenal function relatively quickly. During that phase, owners monitor appetite, thirst and clinical signs closely. Once adequate suppression is reached, the dog moves to a much less frequent maintenance schedule.

The induction phase is not something to improvise from an internet dose chart. The endpoint depends on clinical response and endocrine testing. A dog that stops eating, vomits, develops diarrhea or becomes weak may have reached or passed the desired degree of adrenal suppression and needs veterinary guidance.

Appetite can be a useful treatment signal

Dogs with uncontrolled Cushing’s often have a strikingly increased appetite. Merck Veterinary Manual notes that reduced appetite during mitotane induction can be an important endpoint. Some clinicians ask owners to offer a measured proportion of the usual meal so a change in appetite is easier to recognize.

Complete food refusal is not a target to celebrate. It can signal excessive adrenal suppression or gastrointestinal toxicity and should prompt a call to the veterinary team.

Water intake can also guide monitoring

Excessive drinking and urination are among the most obvious Cushing’s signs. As cortisol production falls, water intake often decreases. Measuring 24-hour water consumption before and during induction can provide more objective information than simply saying the dog “seems less thirsty.”

Do not restrict water to make treatment appear effective. A dog should have normal access to fresh water throughout therapy.

ACTH stimulation testing after induction

After clinical signs suggest sufficient adrenal suppression—or after the veterinarian’s planned induction period—an ACTH stimulation test may be performed to determine whether cortisol response has fallen into the desired range.

Testing helps distinguish successful control from excessive suppression. The exact timing and interpretation should follow the endocrinologist or primary veterinarian’s protocol.

Mitotane versus trilostane

Trilostane inhibits adrenal steroid synthesis without intentionally destroying adrenal tissue and is now the treatment of choice for most dogs with Cushing’s disease. Mitotane remains useful because some patients respond well to it, and Merck notes that certain dogs with calcinosis cutis or atypical hyperadrenocorticism may respond better to mitotane than to trilostane.

The drugs should not be treated as interchangeable. Their induction, monitoring and adverse-effect profiles differ.

Calcinosis cutis and why mitotane may still matter

Calcinosis cutis is a skin complication in which calcium deposits develop in the skin, sometimes causing firm plaques, inflammation or secondary infection. It is uncommon but strongly associated with prolonged corticosteroid excess.

Merck notes that dogs with calcinosis cutis may respond better to mitotane than trilostane. Treatment still requires careful endocrine supervision because the goal is disease control, not maximum adrenal destruction.

Atypical hyperadrenocorticism

Some dogs have clinical signs compatible with Cushing’s disease but unusual endocrine-test patterns or excessive adrenal sex steroids rather than straightforward cortisol excess. These cases are less standardized and deserve specialist interpretation.

Mitotane has historically been used in selected atypical cases. Owners should be wary of broad online claims that any dog with a high adrenal hormone automatically needs mitotane.

Pituitary-dependent disease

Most mitotane-treated dogs have pituitary-dependent hyperadrenocorticism. The drug acts on the adrenal glands downstream of the pituitary signal. It can control cortisol production but does not remove or shrink the pituitary tumor itself.

If a dog develops neurologic signs such as seizures, altered behavior, circling or vision changes, the pituitary tumor may have enlarged. Those signs require separate evaluation and may lead to imaging or radiation therapy.

Adrenal tumors

Functional adrenal tumors can also cause Cushing’s disease. Surgery may be preferred when an adrenal tumor is operable and the dog is a suitable candidate. Merck notes that adrenal tumors can be less responsive to mitotane and may require substantially greater exposure than pituitary-dependent disease.

That makes specialist input especially important. A higher dose is not a home adjustment to make because a dog has an adrenal mass.

Signs of excessive adrenal suppression

Poor appetite, vomiting, diarrhea, weakness, lethargy, shaking and collapse can signal hypoadrenocorticism. If mineralocorticoid production is also affected, sodium can fall and potassium can rise.

Merck specifically advises discontinuing mitotane and providing glucocorticoid support when signs of hypoadrenocorticism occur. Owners should have written instructions about whom to call and what emergency medication, if any, has been prescribed for such situations.

Gastrointestinal adverse effects

Vomiting, diarrhea and anorexia can occur during mitotane therapy even without full Addisonian crisis. These signs are particularly important during induction because they may indicate that the endpoint has been reached or exceeded.

Do not continue the loading schedule through persistent gastrointestinal illness unless the veterinarian has explicitly told you to do so.

Neurologic adverse effects

Ataxia, weakness and seizures have been reported with mitotane. In a dog with a pituitary macroadenoma, neurologic signs can also reflect progression of the brain lesion rather than drug toxicity.

If neurologic abnormalities persist after mitotane is stopped, advanced imaging may be needed to investigate the pituitary region.

Blood sugar changes

Merck notes that mild hypoglycemia can occur during mitotane treatment. Dogs with concurrent diabetes mellitus require especially careful monitoring because reducing cortisol can change insulin resistance and therefore alter insulin needs.

Do not change insulin solely because Cushing’s signs improve. Blood glucose trends and veterinary guidance should determine diabetic adjustments.

Liver enzyme changes

Dogs with Cushing’s disease often have elevated alkaline phosphatase before treatment because of cortisol effects. Mitotane itself can also influence laboratory values. Serial chemistry results are therefore interpreted as trends rather than as one isolated number.

Marked appetite loss, vomiting, jaundice or other signs of systemic illness deserve evaluation rather than being dismissed as expected endocrine changes.

Maintenance treatment

Once adequate adrenal suppression is documented, mitotane is usually given much less frequently than during induction. Maintenance aims to preserve control without causing progressive adrenal destruction.

Dogs on long-term therapy still require periodic ACTH stimulation testing and review of clinical signs. Requirements can change over time.

What if Cushing’s signs return?

Renewed thirst, hunger, panting or skin disease can mean adrenal function has recovered enough that the maintenance plan needs adjustment. It can also mean another disease has emerged.

Do not restart a full induction protocol without veterinary assessment. The clinician may first confirm recurrence with history, examination and endocrine testing.

What if a dose is missed?

During maintenance, one missed dose is usually a different problem from missing several days of induction, but the safest response depends on where the dog is in treatment. Do not double the next amount automatically.

Use the missed-dose guide for general principles and contact the prescribing clinic if the dog is in an active induction phase.

What if an extra dose is given?

Because mitotane intentionally damages adrenal tissue, an accidental extra dose deserves prompt veterinary advice. Contact the clinic or an animal poison service with the exact capsule or tablet strength, amount involved, treatment phase and dog’s weight.

Do not wait for severe weakness or collapse before calling. Excessive adrenal suppression can evolve over hours to days, and early guidance may prevent a more serious crisis.

Why induction instructions should be written down

Mitotane is one of those medicines where verbal instructions alone are easy to misremember. The induction schedule, meal instructions, clinical endpoints and follow-up test date should be written clearly and kept with the medication.

If several household members care for the dog, use a check-off chart. Duplicate administration during induction can be much more consequential than a minor timing variation.

Glucocorticoid rescue plans

Some veterinarians provide a glucocorticoid to keep at home during mitotane induction in case the dog develops signs suggestive of excessive adrenal suppression. If such a plan has been provided, follow the exact instructions rather than improvising with leftover prednisone.

Emergency glucocorticoid use does not replace veterinary assessment when a dog is vomiting repeatedly, weak or collapsing.

Electrolytes and Addisonian risk

If mitotane affects mineralocorticoid-producing adrenal tissue, sodium can fall and potassium can rise. Those changes can cause weakness, dehydration, abnormal heart rhythm and collapse.

Dogs with suspicious clinical signs may need urgent blood chemistry and electrolyte measurement. A normal-looking appetite does not rule out all electrolyte problems, especially in a dog with concurrent disease.

Mitotane and other medications

Dogs with Cushing’s disease are often older and may also receive insulin, antihypertensives, heart medication, NSAIDs or antibiotics. Cortisol reduction can change how the body responds to some of those treatments.

Bring the complete medication list to every recheck. If another veterinarian adds a new drug, make sure they know the dog is receiving mitotane and is being treated for hyperadrenocorticism.

Why skin and coat recovery takes time

Hair regrowth and normalization of thin skin lag behind improvement in thirst and appetite. Owners should not judge treatment failure after only a few weeks because the coat still looks poor.

Secondary skin infections may still need direct treatment. Mineralization, comedones and chronic bacterial or yeast problems can persist even while cortisol control improves.

Muscle weakness and exercise

Chronic cortisol excess causes muscle wasting, so weak hind limbs and reduced exercise tolerance can take months to improve. New sudden weakness during induction is different and can signal excessive adrenal suppression or another medical problem.

Track whether strength is gradually improving or whether it changed abruptly after medication exposure. That timing helps the veterinarian interpret the symptom.

Blood pressure and protein in the urine

Cushing’s disease can be associated with systemic hypertension and proteinuria. Treating cortisol excess may improve those abnormalities, but not always completely.

Blood pressure and urine protein may therefore remain part of follow-up. Persistent hypertension or protein loss may require additional treatment rather than more mitotane.

Clotting risk in Cushing’s disease

Hyperadrenocorticism can create a prothrombotic state. A dog with sudden breathing difficulty, acute limb weakness or collapse needs urgent assessment rather than a routine endocrine dose adjustment.

Antithrombotic treatment, when needed, is a separate clinical decision. Do not add aspirin or clopidogrel without veterinary direction.

What to do before surgery or anesthesia

Tell the anesthetic team that the dog is receiving mitotane and when the last dose was given. Adrenal reserve matters during physiologic stress, and the dog may need specific glucocorticoid support or endocrine reassessment.

Do not decide independently to stop or continue the medicine for a procedure. The recommendation depends on treatment phase and current adrenal function.

Travel during induction is a poor time for improvisation

If possible, avoid starting mitotane induction immediately before travel, boarding or a period when the dog cannot be observed closely. Owners need to recognize changes in appetite, water intake and gastrointestinal signs promptly.

If travel cannot be avoided, carry the written treatment plan, emergency contact information and any rescue medication the veterinarian has prescribed.

When a dog has diabetes mellitus too

Cortisol excess promotes insulin resistance, so controlling Cushing’s disease can lower insulin requirements. A diabetic dog starting mitotane may therefore need closer glucose monitoring than usual.

Hypoglycemia can be dangerous. Do not assume a lower glucose reading means the diabetes is cured; insulin treatment may simply need adjustment as cortisol levels fall.

Why “more suppression” is not better

The goal of mitotane is controlled reduction of pathologic cortisol effects. Destroying additional adrenal tissue after the dog is clinically controlled does not provide extra benefit and increases the risk of permanent hypoadrenocorticism.

This is why maintenance doses and periodic testing matter even when owners feel the dog is doing well.

What to record at home

During induction, record every dose, food intake, water consumption if requested, vomiting, diarrhea, energy and any change in appetite. After transition to maintenance, note recurrence of thirst, hunger, panting or skin problems.

A short dated record helps the veterinarian see treatment response more clearly than relying on memory at the recheck.

Questions to ask before induction starts

Ask exactly what should make you stop mitotane, who to call after hours, when the ACTH stimulation test is scheduled, whether a rescue glucocorticoid has been prescribed and what to do if the dog vomits after a dose.

Also ask whether the dog’s Cushing’s disease is pituitary-dependent or adrenal-dependent and whether surgery or other treatment options have been considered.

Reliable references

The Merck Veterinary Manual Cushing disease chapter describes mitotane induction, monitoring and adverse effects. Merck’s mitotane pharmacology review explains its selective adrenocorticolytic action and the clinical endpoints used during induction.

These references provide general veterinary context. The dog’s own endocrine testing and treatment instructions determine actual use.

Bottom line

Mitotane remains an important but highly supervised treatment for selected dogs with Cushing’s disease. It works by selectively destroying cortisol-producing adrenal tissue, which can control disease effectively but also creates a real risk of excessive adrenal suppression.

Induction should be closely observed, appetite and water changes should be taken seriously, endocrine testing should confirm control, and owners should stop and contact the veterinarian promptly if vomiting, diarrhea, weakness or marked appetite loss develops.

DogMedsHub provides source-backed canine medication guidance and does not diagnose, prescribe or replace veterinary care.

Share